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ABSTRACT 
Chronic kidney disease (CKD) is a syndrome characterized by progressive and irreversible deterioration of renal 
function linked to slow destruction of renal parenchyma, eventually terminating in death when sufficient number 
of nephrons are damaged. Oxidative stress is commonly observed in CKD patients resulting from an imbalance 
between overproduction of reactive oxygen species (ROS) and impairment of defence mechanisms. Grape seed 
extract (GSE) is a polyphenolic mixture exhibiting antioxidant and anti-inflammatory properties. We conducted 
an interventional pilot study of supplementation with GSE capsules (GSE group, n = 23) or placebo (control 
group, n = 10) on CKD patients. Blood and urine samples were collected at baseline and after a six-month-long 
supplementation period to determine some renal function biomarkers, as well as antioxidant, anti-inflammatory 
and haematological parameters. GSE improved glomerular filtration rate (GFR) and proteinuria, increased the 
anti-oxidant status as assessed by high plasma catalase and superoxide dismutase and also lowered lipoperoxida-
tion and carbonylation. GSE ameliorated inflammation by decreasing CRP, triglyceridemia and counteracted 
anemia and thrombocytopenia. Supplementation with 2 g GSE/day for six months improved some kidney func-
tion parameters of CKD patients and this beneficial effect of GSE seems to be mediated at least partly by its an-
tioxidant and anti-inflammatory properties. 
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INTRODUCTION 
Chronic kidney disease (CKD) is a slow 
and progressive decline of kidney function 
that is often linked to long standing diseases 
such as diabetes and hypertension (Remuzzi 
et al., 2002). It is generally characterized by 
high amount of creatinine, low GFR and pro-
teinuria which predict an accelerated loss of 
renal function that irreversibly leads to end 
stage renal disease (Ritz et al., 1999). Oxida-
tive stress and inflammation play important 
roles in both the progress of CKD and relat-
ed complications (Massy and Nguyen-Khoa, 
2002). Oxidative stress results from an im-
balance between ROS overproduction and 
reduced antioxidant defences within mito-
chondria, leading to its dysfunction and con-
sequently to renal cell failure (Wallace, 
2005).  
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Grape seed extract (GSE) is a complex 
polyphenolics mixture containing flavonoïds, 
non flavonoïds, proanthocyanidins exhibiting 
multi-organ protection in various experi-
mental settings (Khanal et al., 2009). For in-
stance, GSE protects the heart (Charradi et 
al., 2011), the liver (Charradi et al., 2014), 
the brain (Charradi et al., 2012) and the kid-
ney (Charradi et al., 2013) against high fat 
diet (HFD)-induced obesity and lipotoxicity 
in rat. Furthermore high dosage GSE was 
even shown to improve renal injury in type 2 
diabetic rats through its anti-oxidant and an-
ti-inflammatory properties (Bao et al., 2015), 
and also to protect against arsenic (Zhang et 
al., 2014), cisplatin (Gao et al., 2014), ami-
kacin (Ulusoy et al., 2012a), and cyclospor-
ine A-induced nephrotoxicity (Ulusoy et al., 
2012b). 
The present work aims to test the ability 
of GSE to improve kidney dysfunction of 
CKD patients from various renal stages i.e 
stage 2, 3, 4. Data mainly show that although 
used at a low dosage, GSE improves several 
kidney function parameters as well as the an-
ti-oxidative status of CKD patients after a 6-
month-supplementation period. 
 
MATERIAL AND METHODS 
Subjects and study design 
CKD patients with renal failure (stages 2, 
3, 4) were recruited as volunteers at the haemo-
dialysis unit of the Regional Hospital of 
Menzel Bourguiba for a randomized double 
blind and placebo control pilot study. All pa-
tients suffered from diabetic nephropathy 
and hypertension. They were treated with in-
sulin (two doses per day), received captopril 
50 mg (2 tablets/day) for hypertension, furo-
semide 40 mg (asylix 2 tablets/day) for 
nephropathy, folic acid (foldine 2 tablets/ 
day) and iron (2 tablets/day) for anemia. Key 
exclusion criteria included smokers and 
haemodialysis patients receiving antioxidant 
supplements in the previous six months. All 
patients were asked to keep their habits and 
medication as usual and were dispatched into 
two groups: experimental and placebo. Pa-
tients in the placebo group (n = 10) were dis-
tributed as follows: 
 3 patients were from stage 2 
(GFR ≤ 90 ml/min/1.73m2) 
 4 patients were from stage 3 
(GFR ≤ 60 ml/min/1.73m2) 
 3 patients were from stage 4 
(GFR ≤ 30 ml/min/1.73m2) 
Patients in the GSE group (n = 23) were 
distributed as follows: 
 6 patients were from stage 2  
 11 patients were from stage 3 
 6 patients were from stage 4 
The GSE group was daily supplemented 
with six capsules of GSE, each capsule con-
taining 350 mg of grape seed powder. Two 
bottles of 90 capsules each were provided to 
each patient for one month during the entire 
six months long study which lasted from 
May to October 2011. The placebo group re-
ceived starch containing capsules in the same 
conditions. Blood samples were withdrawn 
after an overnight fasting at the beginning of 
the study and after 6 months of supplementa-
tion with either GSE or placebo. Urines were 
also collected at baseline and at the end of 
the experimentation for proteinuria determi-
nation. The study protocol was approved by 
the ethics committee on clinical research of 
the Regional Hospital of Menzel Bourguiba 
and informed consent was obtained for all 
participants. The procedures followed were 
in accordance with the Helsinki Declaration 
of 1975, as revised in 2000 and 2008. 
 
GSE preparation 
GSE was processed from a grape cultivar 
(Carignan) of Vitis vinifera from northern 
Tunisia. Seeds were carefully separated from 
skin, washed, dried and grounded with an 
electric grounder until a fine powder was ob-
tained. After mixing with 3 % colloïdal silica 
as excipient, the powder was conditioned in-
to capsules weighting approximately 
350 mg. Total polyphenolics content as well 
as polyphenol composition were determined 
previously (Charradi et al., 2014). 
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Biochemical analyses 
Haematological parameters were deter-
mined on whole blood by using automated 
procedures. GFR was calculated by the Mod-
ification of the Diet Renal Disease (MDRD) 
method. Plasma was processed by centrifu-
gation at 3000 rpm for 10 min and used for 
the determination of renal function bi-
omarkers as urea and uric acid using com-
mercial kits from Biomaghreb, Tunisia. 
Urine urea and uric acid were also deter-
mined and proteinuria evaluated using the 
biuret method (Ohnishi and Barr, 1978). Ox-
idative stress was assessed by measuring 
plasma lipoperoxidation (Draper and Hadley, 
1990), protein carbonylation (Levine et al., 
1990), H2O2 (Kakinuma et al., 1979), free 
iron (Leardi et al., 1998) as well as by meas-
uring antioxidant enzyme activities as cata-
lase (CAT) (Aebi, 1974), superoxide dis-
mutase (SOD) (Misra and Fridovich, 1972) 
and glutathione peroxidase (GPx) (Nakamu-
ra et al., 1974). 
Inflammation was evaluated using plas-
ma CRP and LDH. Triglyceridemia and cho-
lesterolemia were measured using commer-
cial kits from Biomaghreb (Fossati and Pren-
cipe, 1982; Allain et al., 1974) and plasma 
lipase using a previously described method 
(Humbert et al., 1997). 
 
Statistical analysis  
Results were expressed as mean ± SEM. 
Data were compared by a non-parametric 
test (Kruskal-Wallis). P value less than 0.05 
was considered significant. 
 
RESULTS 
We reported in Figure 1 the effect of a 6-
month-long supplementation with GSE on 
some renal hemodynamic parameters of pa-
tients suffering from kidney deficiency. GSE 
increased 1/plasma creatinine ratio by 
19.42 % (Figure 1A, p = 0.044), and de-
creased proteinuria by -32.67 % (Figure 1B, 
p = 0.041) but had no significant effect on 
plasma urea (Figure 1C) and uric acid (Fig-
ure 1D). Moreover GSE slightly improved 
GFR by +18.70 % (36.74 ± 5.74 versus 
43.62 ± 3.68, p = 0.604) (Figure 1E).  
GSE also affected several plasma bi-
omarkers of the antioxidant status. GSE 
slightly decreased plasma MDA by -14.96 % 
(Figure 2A, p = 0.0307), and protein car-
bonylation by -38.82 % (Figure 2B, p = 
0.0319) but had no significant effect on hy-
drogen peroxide (-14 %, Figure 2C, p = 
0.383). Moreover GSE highly increased 
plasma CAT by +95.94 % (Figure 3A, p = 
0.015) and SOD by +25.99 % (Figure 3C, p 
= 0.049) but had no effect on plasma GPx 
activity (Figure 3B).  
 
 
Figure 1: Effect of GSE supplementation on re-
nal function biomarkers of CKD patients. 
1/plasma creatinine ratio (A), proteinuria (B), 
plasma urea (C), plasma uric acid (D) and GFR 
(E). Data are presented as mean ± SEM. GSE 
(after 6 months treatment) vs. GSE (at 0 month): 
*p < 0.05. GSE (after 6 months treatment) vs. 
Placebo (after 6 months treatment): #p < 0.05 
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Figure 2: Effect of GSE supplementation on 
plasma pro-oxidant biomarkers of CKD patients. 
MDA (A), protein carbonylation (B), H2O2 (C). 
Data are presented as mean ±SEM. Placebo (af-
ter 6 months treatment) vs. Placebo (at 0 month): 
§p < 0.05. GSE (after 6 months treatment) vs. 
GSE (at 0 month): *p < 0.05. GSE (after 6 
months treatment) vs. Placebo (after 6 months 
treatment): #p < 0.05 
 
 
Figure 3: Effect of GSE supplementation on 
plasma antioxidant enzyme activities of CKD pa-
tients. CAT (A), GPx (B) and SOD (C) activity. 
Data are presented as mean ± SEM. GSE (after 
6 months treatment) vs. GSE (at 0 month): *p < 
0.05. GSE (after 6 months treatment) vs. Place-
bo (after 6 months treatment): #p < 0.05 
 
We reported in Table 1 the effect of GSE 
on plasma biochemistry and inflammation of 
CKD patients. After a six-month-long treat-
ment period, GSE partially alleviated plasma 
CRP by -12.81 % (+82.83 % for placebo, p = 
0.028 against +56.40 % for GSE, p = 0.168), 
totally counteracted plasma LDH (p = 0.623) 
and increased free iron by +13.26 % (p = 
0.019) versus placebo. Furthermore GSE 
slightly depressed triglyceridemia 
by -16.44 % (p = 0.067), increased plasma 
lipase activity by +29.67 % (p = 0.006), but 
had no effect on cholesterolemia.  
Table 2 reported the effect of GSE on 
some haematological parameters of CKD pa-
tients. GSE slightly increased white blood 
cells (WBC) by +23.48 % (p = 0.276) espe-
cially the granulocytes. GSE also prevented 
anemia of CKD patients. A decrease tenden-
cy in red blood cells (RBC) from 4.72 ± 0.14 
to 4.37 ± 0.19 in control placebo patients (p 
= 0.127) was noticed which was cleaned by 
GSE treatment, allowing the stabilization of 
RBC from 4.22 ± 0.21 ( control 0 month 
GSE) to 4.23 ± 0.25 (6 months treatment 
GSE) (p = 0.692). Furthermore GSE did not 
affect haemoglobin nor did it prevent the de-
crease in haematocrit of CKD patients from 
39.33 ± 0.81 to 35.53 ± 0.96 in control (p = 
0.016) and from 37.22 ± 0.84 to 33.30 ± 1.42 
in GSE treated patients (p = 0.049). However 
GSE significantly counteracted thrombocy-
topenia by +24.63 % (p = 0.030) when com-
pared to placebo which increased platelets by 
+10.93 % (p = 0.327).  
We reported in Table 3 the effect of a 
six-month-long GSE treatment on kidney 
function biomarker as GFR. The initial num-
ber of stage 4 and 3 patients tend to decrease 
from 6 to 2 and from 11 to 10 patients re-
spectively reaching an overall number of 5 
patients who swell the ranks of stage 2, ris-
ing the cohort of stage 2 patients from 6 to 
11 representing + 83.33 %. No GFR change 
(no improvement nor worsening) occurred in 
the placebo group.  
 
DISCUSSION 
The present work is a preliminary and pi-
lot study dealing with the effect of GSE 
treatment on CKD patients of various renal 
failure stages. Data mainly show that even 
when used at a low dosage, GSE exerts a 
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Table 1: Effect of GSE on anthropometric parameters, plasma biochemistry and inflammation of CKD patients 
 
0 month After 6 months treatment p-value 
Placebo 
(n = 10) 
GSE 
(n = 23) 
Placebo 
(n = 10) 
GSE 
(n = 23) 
(Placebo(6 months) 
vs. Placebo(0 month))
(GSE (6 months) vs. 
GSE (0 month)) 
(GSE (6 months) vs. 
Placebo (6 months)) 
Age (years) 62.7 ± 2.4 62.3 ± 1.9      
Weight (kg) 80.4 ± 5.5 74.1 ± 2.7      
Sex ratio (M/F) 6/4 13/10      
BP max (cm Hg) 16.1 ± 0.3 15.7 ± 0.2 16.1 ± 0.3 15.7 ± 0.2 1.000 1.000 1.000 
BP min (cm Hg) 8.3 ± 0.3 8.3 ± 0.1 8.3 ± 0.3 8.3 ± 0.1 1.000 1.000 1.000 
Glycemia (mmol/L) 6.9 ± 1.2 7.8 ± 0.9 6.7 ± 1.1 7.3 ± 0.7 0.423 0.050 0.507 
CRP (mg/L) 1.8 ± 0.3 1.8 ± 0.5 3.3 ± 0.2 § 2.9 ± 0.3 0.028 0.161 0.678 
LDH (U/L) 308.5 ± 30.6 305.9 ± 16.9 330.1 ± 55.4 307.6 ± 39.2 0.609 0.623 0.625 
Free iron (µmol/L) 12.0 ± 1.1 12.7 ± 0.7 15.1 ± 0.9 17.1 ± 0.5 * 0.234 0.019 0.461 
Triglyceride (mmol/L) 1.8 ± 0.4 1.8 ± 0.1 1.8 ± 0.4 1.5 ± 0.1 0.624 0.067 0.969 
Cholesterol (mmol/L) 4.7 ± 0.8 4.9 ± 0.2 5.0 ± 0.4 5.1 ± 0.2 0.522 0.331 0.640 
Lipase (µmol/L) 6.8 ± 0.5 8.1 ± 0.7 6.9 ± 0.3 8.9 ± 0.5 * 0.584 0.006 0.254 
BP: Blood pressure; CRP: C-Reactive Protein; LDH: Lactate Dehydrogenase. Data are presented as mean ± SEM. Placebo (after 6 months treatment) vs. Placebo (at 0 month): §p < 0.05. 
GSE (after 6 months treatment) vs. GSE (at 0 month): *p < 0.05. 
 
 
 
 
 
 
 
 
 
 
EXCLI Journal 2016;15:424-433 – ISSN 1611-2156 
Received: April 30, 2016, accepted: June 07, 2016, published: June 27, 2016 
 
 
429 
Table 2: Effect of GSE on CKD patients hematology 
 
0 month After 6 months treatment p- value 
Placebo 
(n = 10) 
GSE 
(n = 23) 
Placebo 
(n = 10) 
GSE 
(n = 23) 
(Placebo(6 months) 
vs. Placebo(0 month))
(GSE (6 months) vs. 
GSE (0 month)) 
(GSE (6 months) vs. Place
bo (6 months)) 
WBC (x10³/µl) 6.62 ± 0.99 6.77 ± 0.40 6.18 ± 0.77 7.63 ± 0.66 0.688 0.276 0.189 
LY# (x10³/µl) 2.30 ± 0.33 2.87 ± 0.29 2.33 ± 0.29 2.39 ± 0.23 0.749 0.220 0.827 
MO# (x10³/µl) 0.22 ± 0.05 0.27 ± 0.04 0.26 ± 0.06 0.22 ± 0.04 0.636 0.461 0.497 
GR# (x10³/µl) 4.14 ± 0.65 3.26 ± 0.33 3.63 ± 0.48 3.37 ± 0.78 0.749 0.958 0.897 
RBC (x106/µl) 4.72 ± 0.14 4.22 ± 0.21 4.37 ± 0.19 4.23 ± 0.25 0.127 0.692 0.574 
Hgb (g/dl) 12.87 ± 0.35 11.76 ± 0.57 13.03 ± 0.33 12.62 ± 0.69 0.872 0.531 0.302 
Hct (%) 39.33 ± 0.81 37.22 ± 0.84 35.53 ± 0.96 § 33.30 ± 1.42 * 0.016 0.049 0.269 
MCV (fl) 83.72 ± 3.03 78.77 ± 4.90 81.57 ± 1.75 77.94 ± 4.70 0.200 0.869 0.779 
MCH (pg) 27.37 ± 1.17 27.88 ± 0.56 29.92 ± 0.69 30.67 ± 0.77 * 0.065 0.014 0.673 
MCHC (g/dl) 32.65 ± 0.35 32.97 ± 0.50 36.68 ± 0.10 § 36.71 ± 0.34 * 0.004 <0.001 0.724 
RDW (%) 14.06 ± 0.49 13.31 ± 0.13 14.42 ± 0.33 13.74 ± 0.40 0.927 0.677 0.049 
PLT (x10³/µl) 196.56 ± 16.41 188.10 ± 12.61 218.00 ± 18.68 234.43 ± 13.05* 0.327 0.030 0.537 
MPV (fl) 8.20 ± 0.46 8.43 ± 0.31 8.40 ± 0.48 8.12 ± 0.17 0.630 0.620 0.542 
Data are presented as mean ± SEM. Placebo (after 6 months treatment) vs. Placebo (at 0 month): §p < 0.05. GSE (after 6 months treatment) vs. GSE (at 0 month): *p < 0.05.  
WBC: white blood cells; LY#: lymphocytes; MO#: monocytes; GR#: granulocytes; RBC: red blood cells; Hgb: haemoglobin; Hct: haematocrit; MCV: mean cell volume; MCH: mean cell haemoglobin; 
MCHC: mean cell hemoglobin concentration; RDW: red cell distribution width; PLT: platelets; MPV: mean platelet volume  
 
Table 3: Effect of GSE on the progression of CKD stages 
Stage GFR 
0 month After 6 months treatment 
Placebo (n = 10) GSE (n = 23) Placebo (n = 10) GSE (n = 23)
2 60 ≤ GFR ≤ 90 mL/min/1.73 m2 3 6 3 11 (+5) 
3 30 ≤ GFR ≤ 60 mL/min/1.73 m2 4 11 4 10 (-1) 
4 15 ≤ GFR ≤ 30 mL/min/1.73 m2 3 6 3 2 (-4) 
GFR: Glomerular Filtration Rate 
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clear beneficial effect on some renal function 
biomarkers as well as on the antioxidant sta-
tus of CKD patients. To our knowledge, our 
work is the first one to describe such relevant 
and hopeful clinical trials data for million 
CKD patients worldwide.  
First of all GSE improves some kidney 
function parameters as it enhances GFR and 
clearly lowers proteinuria. This result is of 
utmost importance as reduction in pro-
teinuria to the lowest achievable level is an 
important predictor of long term renal pro-
tection (de Zeeuw et al., 2004), as it is in-
creasingly recognized that proteinuria may 
actually be pathological and etiological in 
CKD progress and not just symptomatic 
(Roscioni et al., 2014). An association be-
tween hyperuricemia and CKD in middle-
aged population has also been recently de-
scribed (Zhu et al., 2014). As in our present 
case GSE affects both plasma, urine urea and 
uric acid, its clinical use could be envisaged 
as an uric acid-lowering therapy substitute to 
allopurinol. 
The beneficial effect of GSE on renal 
function seems to be mediated, at least par-
tially, by its antioxidant and anti-inflamma-
tory properties. After a six-month-period of 
treatment, GSE counteracts both plasma 
lipoperoxidation and carbonylation as well 
as CRP and LDH, and clearly increases 
plasma CAT and SOD (Rodrigo and Bosco, 
2006). Moreover GSE improves some blood 
parameters that were shown to be linked to 
CKD as anemia (Tbahriti et al., 2013), 
thrombocytopenia (Attman et al., 2011), hy-
pertriglyceridemia (Stegmayr, 2014) and low 
plasma lipase activity (Dorgalaleh et al., 
2013). Importantly no patient drop out of the 
study nor adverse side effects were noted 
during the entire clinical trial period. Our da-
ta corroborate several previous works in the 
field demonstrating the heightening of oxida-
tive and inflammatory biomarkers along with 
a decrease in antioxidant biomarkers in CKD 
patients. As rightly emphasized (Rodrigo and 
Bosco, 2006), only few studies dealing with 
the effect of polyphenols in humans are 
available, and our contribution is the first to 
show the effectiveness of GSE to improve 
renal function in CKD patients from various 
clinical stages. As a support, dietary supple-
mentation with concentrated red grape juice 
was shown to exert antioxidant and anti-
inflammatory effect in haemodialysis pa-
tients (Castilla et al., 2008). Moreover our 
data are in line with recent animal studies 
demonstrating the usefulness of grape seed 
polyphenols in the improvement of renal 
dysfunction (Bao et al., 2015; Zhang et al., 
2014; Gao et al., 2014; Ulusoy et al., 2012a, 
b). In particular the use of high dosage GSE 
(higher than 500 mg/kg) was recently shown 
to exert relevant beneficial health effects 
(Jhun et al., 2013; Tsao et al., 2012; Yang et 
al., 2012) whereas lower dosages were less 
effective (Goey et al., 2013). 
Remarkably that in our present case, 
GSE improvement in kidney function of 
CKD patients has been obtained at a low 
GSE dosage of 35 mg/kg if we consider the 
weight of the starting grape seed powder, 
and highly lower if we consider the polyphe-
nol content. Our laboratory has recently 
demonstrated the efficiency of high dosage 
GSE (till 4 g/kg) in multi-organ protection 
against various insults as obesity (Charradi et 
al., 2011, 2012, 2013), stroke (Safwen et al., 
2015), or chemotherapeutic treatment (Mok-
ni et al., 2012). In fact, our studies were in-
spired from the pionneering work of Bagchi 
et al. (2000) and other subsequent studies 
that led to the elaboration of calibrated and 
commercial GSE preparations which evi-
denced the safety of high dosage GSE (till 
2 g/kg) in long-term experiments (Benti-
vegna and Whitney, 2002). In light of these 
data it appears that the concentration of GSE 
used in the present study (35 mg/kg) is far 
less from the No Observed Adverse Effect 
Level (NOAEL) of IH 636 or oligonol GSE 
preparation (Fujii et al., 2007). In addition as 
GSE recently received the Generally Recog-
nized As Safe (GRAS) certification from US 
FDA (2011), its use opens a new and safe 
approach for the validation of high dosage 
GSE to impede CKD. Most importantly and 
although used at very low level, GSE seems 
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to slow down the progression of CKD and 
even to reverse the decline in kidney func-
tion (Choi et al., 2014) as described in the 
present pilot study i.e from stages 4 and 3 to 
stage 2. 
Nevertheless the current interventional 
pilot study suffers from several limitations. 
First the sample size is too small to be of ro-
bust statistical significance. Although GSE 
was used at low dosage, a significant im-
provement in the decline of some kidney 
function biomarkers after a six-month-
treatment period was obtained. Duration of 
the study should be extended to increase 
blood and urine sampling and a ten fold 
higher GSE dosage (350 mg/kg) should be 
tested to reach improvement of statistical 
significance. Owing to its tremendous safety, 
GSE is increasingly used at high dosage 
(more than 500 mg/kg) according to our own 
data (Charradi et al., 2011, 2014, 2012, 
2013) or to current literature (Li et al., 2015; 
Mansouri et al., 2011; Margalof et al., 2015). 
In conclusion, due to the multi-organ 
safety and beneficial health effects of grape 
polyphenols, clinical trials using high GSE 
dosage should be urgently planned to con-
firm these preliminary and hopeful data. 
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